Sitagliptin (Januvia) for Type 2 Diabetes — Weight & Metabolism
First DPP-4 inhibitor with proven cardiovascular safety from the TECOS trial, offering well-tolerated glucose control without hypoglycemia or weight gain.
Overview
Sitagliptin was the first DPP-4 inhibitor approved (2006) and remains the most widely prescribed in its class. It works by inhibiting dipeptidyl peptidase-4, prolonging active GLP-1 and GIP to enhance glucose-dependent insulin secretion and suppress glucagon. The TECOS trial (n=14,671, median 3.0 years) confirmed cardiovascular safety with no increased risk of MACE (HR 0.98, 95% CI 0.89-1.08) or heart failure hospitalization. Model-based meta-analysis of 25 trials (n=11,234) showed placebo-adjusted HbA1c reduction of -0.81%. Weight neutral, low hypoglycemia risk as monotherapy, and once-daily dosing make it an excellent option for patients prioritizing tolerability. PMID: 26052984, 23818159.
Indications
- Type 2 diabetes mellitus as monotherapy or combination with metformin, sulfonylureas, thiazolidinediones, or insulin
- Patients prioritizing medication tolerability and low side effect profile
- Elderly patients or those at high hypoglycemia risk who need modest glycemic improvement
- Add-on therapy when metformin alone insufficient and GLP-1 RA or SGLT2i not preferred
Mechanism of Action
Active GLP-1 and GIP are rapidly degraded by DPP-4 enzyme (half-life 1-2 minutes), reducing glucose-dependent insulin secretion
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Sitagliptin (Januvia) | 100 mg | Once daily | Standard dose for eGFR >=45; with or without food |
| Sitagliptin (Januvia) | 50 mg | Once daily | eGFR 30-44 mL/min/1.73m2 |
| Sitagliptin (Januvia) | 25 mg | Once daily | eGFR <30 including dialysis; one of few diabetes meds safe on dialysis |
Evidence Grade
GRADE A
Safety & Contraindications
- FDA-approved since 2006 with excellent long-term safety record (TECOS trial)
- Cardiovascular safety confirmed: no increase in MACE or heart failure (unlike saxagliptin/SAVOR-TIMI 53)
- Low hypoglycemia risk as monotherapy or with metformin (glucose-dependent mechanism)
- Weight neutral: no significant weight gain or loss vs placebo
- Rare reports of severe joint pain (arthralgia) - FDA safety communication 2015; usually resolves on discontinuation
- Rare acute pancreatitis: monitor for severe abdominal pain; risk similar to background rate in T2DM population